Yasir Y Elamin | MD Anderson Cancer Center

Dr. Yasir Y. Elamin

Claim this profile

M D Anderson Cancer Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
15 drugs studied

Area of expertise

1

Lung Cancer

Yasir Y. Elamin has run 8 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III
2

Non-Small Cell Lung Cancer

Yasir Y. Elamin has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
HER2 positive

Affiliated Hospitals

Image of trial facility.

M D Anderson Cancer Center

Image of trial facility.

MD Anderson Cancer Center - The University Of Texas PHASE 2

Clinical Trials Yasir Y. Elamin is currently running

Image of trial facility.

NVL-655

for NSCLC

This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.

Recruiting

1 award

Phase 1 & 2

7 criteria

Image of trial facility.

Repotrectinib

for Solid Tumors

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Recruiting

1 award

Phase 1 & 2

7 criteria

More about Yasir Y. Elamin

Clinical Trial Related

5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Yasir Y. Elamin has experience with

  • Brigatinib
  • Carboplatin
  • Pemetrexed
  • Osimertinib
  • Poziotinib
  • Bevacizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Yasir Y. Elamin specialize in?

Is Yasir Y. Elamin currently recruiting for clinical trials?

Are there any treatments that Yasir Y. Elamin has studied deeply?

What is the best way to schedule an appointment with Yasir Y. Elamin?

What is the office address of Yasir Y. Elamin?

Is there any support for travel costs?